FIELD: medicine.
SUBSTANCE: presented group of inventions refers to medicine, namely to oncology. Disclosed is a method for predicting the response of a patient diagnosed with an oncological disease to an anticancer therapy with a PARP inhibitor by determining a relative level of tumour cells with foci of RAD51. Disclosed is a method for selecting an individual therapy and a method for classifying a patient. Disclosed is a method for predicting the ability of a patient’s tumour to repair DNA by homologous recombination. Disclosed is a kit for implementing said methods, comprising an antibody capable of specifically recognizing the RAD51 protein and an antibody capable of specifically recognizing the Geminin protein and/or γH2AX.
EFFECT: presented group of inventions provides detection of tumours which are resistant and sensitive to PARP inhibitors, by determining the level of tumour cells with RAD51 foci.
65 cl, 10 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING PANCREATIC CANCER AND NON-SMALL CELL LUNG CANCER WITH ATR INHIBITORS | 2012 |
|
RU2648507C2 |
| METHOD OF TREATING BREAST CANCER WITH COMPOUND OF 4-IODINE-3-NITROBENZAMINE IN COMBINATION WITH ANTICANCER AGENTS | 2008 |
|
RU2480211C2 |
| METHOD OF TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | 2015 |
|
RU2736219C2 |
| DNA REPAIR INHIBITORS FOR CANCER THERAPY | 2004 |
|
RU2413515C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| INHIBITORS OF DNA DAMAGE REPAIR FOR CANCER TREATMENT | 2017 |
|
RU2755865C2 |
| METHOD FOR DETECTING INDIVIDUAL RADIOSENSITIVITY OF PATIENTS WITH MALIGNANT GROWTHS IN RADIATION THERAPY | 2012 |
|
RU2522507C1 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF MALIGNANT TUMOUR | 2013 |
|
RU2660349C2 |
